- Home
- ARTW vs CANF Comparison
ARTW vs CANF Comparison
Compare ARTW & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTW
- CANF
- Stock Information
- Founded
- ARTW 1956
- CANF 1994
- Country
- ARTW United States
- CANF Israel
- Employees
- ARTW N/A
- CANF N/A
- Industry
- ARTW Industrial Machinery/Components
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- ARTW Industrials
- CANF Health Care
- Exchange
- ARTW Nasdaq
- CANF Nasdaq
- Market Cap
- ARTW 8.0M
- CANF 7.9M
- IPO Year
- ARTW N/A
- CANF N/A
- Fundamental
- Price
- ARTW $1.50
- CANF $1.18
- Analyst Decision
- ARTW
- CANF Strong Buy
- Analyst Count
- ARTW 0
- CANF 2
- Target Price
- ARTW N/A
- CANF $14.00
- AVG Volume (30 Days)
- ARTW 33.5K
- CANF 408.4K
- Earning Date
- ARTW 04-09-2025
- CANF 05-06-2025
- Dividend Yield
- ARTW N/A
- CANF N/A
- EPS Growth
- ARTW N/A
- CANF N/A
- EPS
- ARTW 0.14
- CANF N/A
- Revenue
- ARTW $23,916,932.00
- CANF $674,000.00
- Revenue This Year
- ARTW N/A
- CANF $461.72
- Revenue Next Year
- ARTW N/A
- CANF N/A
- P/E Ratio
- ARTW $31.75
- CANF N/A
- Revenue Growth
- ARTW N/A
- CANF N/A
- 52 Week Low
- ARTW $1.33
- CANF $1.22
- 52 Week High
- ARTW $4.15
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- ARTW 48.25
- CANF 37.60
- Support Level
- ARTW $1.48
- CANF $1.14
- Resistance Level
- ARTW $1.67
- CANF $1.27
- Average True Range (ATR)
- ARTW 0.10
- CANF 0.12
- MACD
- ARTW 0.01
- CANF -0.02
- Stochastic Oscillator
- ARTW 56.00
- CANF 6.03
About ARTW Art's-Way Manufacturing Co. Inc.
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products, and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).